Artiva Biotherapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
/ 
Frequently asked questions
To buy Artiva Biotherapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Artiva Biotherapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Artiva Biotherapeutics Inc. is ARTV:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Artiva Biotherapeutics Inc. has its primary listing on NASDAQ. You can trade Artiva Biotherapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Artiva Biotherapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Artiva Biotherapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Artiva Biotherapeutics Inc..